Inhaled RB042 Tested in Healthy Adults and People With COPD

Trial details

Who runs it

Atisama Therapeutics

Trial code

NCT07285122

Record updated

12 August 2026

Original description

This is a 4-part, randomised, double-blind, placebo-controlled, first in human study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of inhaled RB042.Read full original descriptionShow less

A Phase 1a/1b, Randomised, Double Blind, Placebo-controlled, Dose-escalating Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of RB042 Administered Via Inhalation to Healthy Adult Volunteers, Healthy Adult Smokers and Patients With Chronic Obstructive Pulmonary Disease

This is a 4-part, randomised, double-blind, placebo-controlled, first in human study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of inhaled RB042.

Inclusion: Part A, B, C only: Participants must be 18 to 55 years of age inclusive; Part D only: Patients must be 40 to 80 years of age inclusive; Part A, B, C only: Participants must be overtly healthy as determined by medical evaluation; Part C only: have a ≥10 pack years smoking history, have smoked tobacco products (cigarettes, cigars, or equivalent) regularly for the past 12 months, and currently smoke daily; Part D only: Former smokers (smoked a total of 100 or more cigarettes in their lifetime but has not smoked in the past 6 months to over a year); Part A, B, C only: Have forced expiratory volume (FEV1) ≥80% predicted and FEV1 to FVC ratio (FEV1/FVC) ≥0.7 at Screening and on Day -1; Part D only: Have forced expiratory volume (FEV1) between ≥30% and <80% predicted and FEV1 to FVC ratio (FEV1/FVC) <0.7 post-bronchodilation at Screening; Part D only: Documented clinical diagnosis of COPD per 2026 Global Initiative for Chronic Obstructive Lung Disease (GOLD) for greater than ≥1 year and a history of chronic bronchitis as evidenced by frequent productive cough in the 2-year period immediately before Screening; Part D only: Have clinically stable COPD with no moderate to severe exacerbations in the past 3 months; Part D only: Must be on stable assigned maintenance COPD therapy; Body weight at least 50 kg and have a body mass index (BMI) within the range 18.0 and 32.0 kg/m2 (inclusive); Women of childbearing potential (WOCBP) must have a negative pregnancy test and must not be lactating; Participants must agree to use an approved method(s) of highly effective contraception as defined in the protocol.

Exclusion: Active respiratory infection within 5 days before study start; Recent or concurrent use of medications, herbal supplements, vaccines, or blood products that could interfere with study safety or interpretation; Parts A, B and D only: Regular smoking (≥1 day per week) within 6 months prior to dosing, or a positive urine cotinine test at screening or Day -1; Part A, B and C only: Clinically significant history or presence of gastrointestinal, hepatic, renal, cardiovascular, respiratory, endocrine, neurologic, hematologic, metabolic, autoimmune, or oncologic disorders that may affect safety or study outcomes; Part D only: Current unstable clinically significant history or presence of gastrointestinal, hepatic, renal, cardiovascular, respiratory, endocrine, neurologic, hematologic, metabolic, autoimmune, or oncologic disorders that may affect safety or study outcomes; Part A, B and C only: Chronic or active respiratory disease (e.g., asthma, COPD) or history of angioedema within 3 years; Part D only: Patients with other respiratory conditions other than COPD (for example, clinically significant asthma, active tuberculosis, pulmonary fibrosis) are excluded if these conditions are the primary cause of their respiratory symptoms; Positive test for hepatitis B surface or core antigen, hepatitis C (unless HCV-RNA negative), or HIV; History of severe drug reaction or anaphylaxis; Any psychiatric or medical condition that, in the investigator's opinion, could compromise safety or compliance; Active or chronic liver disease, or abnormal liver function tests (ALT, AST, or bilirubin outside reference range, except Gilbert's syndrome); Renal impairment (creatinine clearance <90 mL/min) or thrombocytopenia (<150 × 10⁹/L); QTcF >450 msec (males) or >470 msec (females); Participation in another investigational study within 30 days, or blood donation >400 mL within 30 days; Excessive alcohol consumption (>21 drinks/week for males or >14 for females); Part B and C only: Contraindication to, or unwillingness to undergo, bronchoscopy.

ClinicalTrials.gov NCT07285122